The clinical presentations of both liver disease and pancreatitis are nonspecific and overlapping, which may cause difficulty in diagnosis. In our retrospective pilot study, we assessed whether dogs with evidence of portal hypertension and absence of pancreatitis on pancreatic histology have increases in canine pancreatic lipase immunoreactivity (cPLI) and 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6′-methylresorufin) ester (DGGR) lipase. We included dogs that had been presented between 2008 and 2019 if they had normal pancreatic histology, histologically confirmed hepatopathy, and if canine pancreas-specific lipase (Spec cPL; Idexx) or DGGR lipase had been measured. Only dogs with portal hypertension were included. Six dogs fulfilled the inclusion criteria. Four of 6 and 2 of 6 dogs had Spec cPL and DGGR lipase exceeding the upper reference limit, respectively. From the 4 dogs with increased Spec cPL, 2 had concentrations of 200–400 µg/L and 2 had concentrations ≥ 400 µg/L. Our results suggest that canine portal hypertension might lead to increased Spec cPL and DGGR lipase values in the absence of pancreatitis on histology. Until more evidence in a larger number of dogs with portal hypertension is available, both tests should be interpreted cautiously in the presence of portal hypertension.

肝病和胰腺炎的临床表现均无特异性且重叠，可能导致诊断困难。在我们的回顾性试验研究中，我们评估了有门静脉高压症和胰腺组织学无胰腺炎证据的狗是否增加了犬胰脂肪酶免疫反应性 (cPLI) 和 1,2-o-二月桂酰-rac-甘油-3-戊二酸- (6'-甲基试卤灵)酯 (DGGR) 脂肪酶。我们纳入了 2008 年至 2019 年间出现的犬，如果它们的胰腺组织学正常、组织学证实有肝病，并且是否已测量犬胰腺特异性脂肪酶 (Spec cPL; Idexx) 或 DGGR 脂肪酶。仅包括门静脉高压症的狗。六只狗符合纳入标准。6 只狗中有 4 只和 6 只狗中有 2 只的 Spec cPL 和 DGGR 脂肪酶分别超过了参考上限。在 Spec cPL 增加的 4 只狗中，2 只的浓度为 200–400 µg/L，2 只的浓度≥ 400 µg/L。我们的结果表明，在组织学上没有胰腺炎的情况下，犬门静脉高压可能导致 Spec cPL 和 DGGR 脂肪酶值增加。在获得更多门静脉高压症犬的证据之前，在门静脉高压症存在的情况下应谨慎解释这两项测试。